BIO Announces New Leadership for Food and Agriculture Section Governing Board
Washington, D.C. (July 29, 2020) – The Food and Agriculture Section of the Biotechnology Innovation Organization (BIO) is pleased to announce the election of its new Board leadership.
Sylvia Wulf, CEO of AquaBounty Technologies, Inc., and Brian Brazeau, President of Novozymes North America, were elected as the new Chair and Vice Chair, respectively, of BIO’s Food and Agriculture Section Governing Board. Wulf and Brazeau will also serve as BIO Executive Committee members for the 2020-2021 term.
“I’m excited to welcome Sylvia and Brian to the leadership of BIO’s Food and Agriculture Section. They are highly experienced and respected individuals who are dedicated to moving biotech innovation forward,” said Dana O’Brien, Executive Vice President, Food and Agriculture Section. “Their companies represent the best of BIO’s diverse membership.”
“Using biology to build resilient food and farming systems and a robust biobased economy is more critical now than ever before. COVID-19 continues shining a bright light on vulnerabilities we didn’t take time to imagine a few months ago,” said Wulf. “Access to basic human needs, such as food and healthcare, are threatened, and racial disparities are being painfully exposed. As chair of the Food and Agriculture Section, I will work with my peers and BIO to speed biotech innovations that improve the human condition.”
“At Novozymes, we believe this century will be the age of biology. By using enzymes and microbial technologies in food and agriculture, we can increase efficiencies, reduce harmful emissions and energy use, and decrease the need for pesticides, without compromising performance or quality,” said Brazeau. “By further progressing bioinnovation in animal health, crop protection, and alternative proteins, the industry stands with an incredible opportunity to deliver solutions that match the emerging, global needs of the future.”
The Food and Agriculture Section also welcomes Elena Rice, Chief Science Officer and Head of Research & Development for Genus PLC, as a new member of the Board, and thanked outgoing chair, Phil Miller of Bayer, for his dedication to innovation and service to BIO.
